Izraēla - angļu - Ministry of Health

takeda israel ltd - icatibant as acetate - solution for injection - icatibant as acetate 30 mg / 3 ml - icatibant - symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 -esterase-inhibitor deficiency

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - injection, diluent for - excipient ingredients: water for injections - zemaira is an alpha1-proteinase inhibitor (a1-pi) indicated for chronic augmentation and maintenance therapy in adults with a1-pi deficiency and clinical evidence of emphysema.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, hereditary - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - icatibant acetate, quantity: 31.38 mg (equivalent: icatibant, qty 30 mg) - injection, solution - excipient ingredients: glacial acetic acid; sodium chloride; water for injections; sodium hydroxide - fyzant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older with c1-esterase-inhibitor deficiency.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - icatibant acetate, quantity: 31.38 mg (equivalent: icatibant, qty 30 mg) - injection, solution - excipient ingredients: sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - cipla icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older with c1-esterase-inhibitor deficiency.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - icatibant acetate, quantity: 31.38 mg (equivalent: icatibant, qty 30 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; glacial acetic acid; sodium chloride - icatibant lupin is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older with c1-esterase-inhibitor deficiency.

Izraēla - angļu - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - powder and solvent for solution for injection - c - 1 esterase inhibitor human 2000 iu/vial - c1- inhibitor,plasma derived - prevention of recurrent hereditary angioedema (hae) attacks in adolescent and adult patients with c1-esterase inhibitor deficiency.

Izraēla - angļu - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - powder and solvent for solution for injection - c - 1 esterase inhibitor human 3000 iu/vial - c1- inhibitor,plasma derived - prevention of recurrent hereditary angioedema (hae) attacks in adolescent and adult patients with c1-esterase inhibitor deficiency.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

diagnostica stago pty ltd - ct876 - thrombophilia and coagulation inhibitor ivds - ivds that are intended to be used in testing to provide information about thrombosis or the abnormal development of clots, and inhibitors of the coagulation process.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct876 - thrombophilia and coagulation inhibitor ivds - for in vitro diagnostic use in the quantitatvie and/or qualitative determination of thrombosis or the abnormal development of clots, and inhibitors of the coagulation process.